Current status of human papillomavirus vaccination implementation in central and eastern Europe

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 22, Issue 1, 2013, Pages 21-25

  Seme, Katja ^a   Maver, Polona J ^a   Korać, Tina ^a   Canton, Amalia ^b   Částková, Jitka ^c   Dimitrov, Goran ^d   Filippova, Irina ^e   Hudecová, Helena ^f   Iljazović, Ermina ^g   Kaić, Bernard ^h   Kesić, Vesna ^i,j   Kuprevičiene, Nerija ^k   Laušević, Dragan ^l   Molnár, Zsuzsanna ^m   Perevoščikovs, Jurijs ⁿ   Spaczyński, Marek ^o   Stefanova, Venera ^p   Učakar, Veronika ^q   Poljak, Mario ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Ministry of Health   (Romania)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^d University Clinic of Gynecology and Obstetrics   (Macedonia)

^e Health Board ^*  (Estonia)

^f Public Health Authority of the Slovak Republic   (Slovakia)

^g University Clinical Center   (Bosnia and Herzegovina)

^h CROATIAN NATIONAL INSTITUTE OF PUBLIC HEALTH   (Croatia)

ⁱ UNIVERSITY OF BELGRADE   (Serbia)

^j CLINICAL CENTER OF SERBIA   (Serbia)

^k VILNIUS UNIVERSITY   (Lithuania)

^l Institute of Public Health   (Montenegro)

^m NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

ⁿ Centre for Disease Prevention and Control   (Latvia)

^o POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^p NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^q NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ALBANIA; BOSNIA AND HERZEGOVINA; BULGARIA; CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; CROATIA; CZECH REPUBLIC; DRUG COST; EASTERN EUROPE; ESTONIA; HUMAN; HUNGARY; INFECTION PREVENTION; LATVIA; LITHUANIA; MACEDONIA (REPUBLIC); MONTENEGRO (REPUBLIC); PAPILLOMAVIRUS INFECTION; POLAND; PREVENTIVE HEALTH SERVICE; REVIEW; ROMANIA; SERBIA; SLOVAKIA; SLOVENIA; UTERINE CERVIX CANCER;

CHILD; DATA COLLECTION; EUROPE, EASTERN; FEMALE; HUMANS; MALE; NATIONAL HEALTH PROGRAMS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84878046933     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10162-012-0026-z     Document Type: Review

References (15)

1. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med. 2007;356:1915-27.
2. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papilloma virus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-70. (Pubitemid 46977438)
3. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009:374:301-14.
4. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-66. (Pubitemid 44863348)
5. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;11:1915-23. (Pubitemid 39458555)
6. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine. 2012;30(Suppl 5):F139-48.
7. Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya S, et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in central and eastern Europe. Vaccine. 2013 (in press).
8. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. VENICE 2 project gatekeepers group. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE 2 2010 survey. Euro Surveill. 2010;15:19730.
9. Obradovic M, Mrhar A, Kos M. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. Eur J Public Health. 2010;20:415-21.
10. Prymula R, Anca I, André F, Bakir M, Czajka H, Lutsar I, et al. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. Eur J Pediatr. 2009;168:1031-5.
11. Human Papillomavirus and Related Cancers in Albania. Summary Report 2010 [Internet]. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). c2010 - [cited 2013 Feb 24]. Available from: http://www.who.int/hpvcentre.
12. The National Cancer Control Program 2011-2020 [Internet]. Republic of Albania, Ministry of Health. c2011 - [cited 2013 Feb 24]. Available from: http://www.thewpca.org/.
13. Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ. 2010;13:110-8.
14. Vokó Z, Nagyjánosi L, Kaló Z. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health. 2012;12:924.
15. Polish Gynaecological Society Guidelines for HPV vaccination. Ginekol Pol. 2009;80:139-46.